Australian Medical Research and Innovation Priorities 2016 – 2018 Determination 2016 (Cth)
Australian Medical Research and Innovation Priorities 2016 – 2018 Determination 2016
I, Ian Frazer, Chair of the Australian Medical Research Advisory Board, make the following instrument on behalf of the Advisory Board, under subsection 32E(1) of the Medical Research Future Fund Act 2015.
Dated: 7 November 2016
Professor Ian Frazer, AC
Chair, Australian Medical Research Advisory Board
Contents
1.Name of Instrument....................................................................................................... 3
2.Commencement............................................................................................................. 3
3.Cessation....................................................................................................................... 3
4.Authority....................................................................................................................... 3
5.Schedules...................................................................................................................... 3
Schedule 1.................................................................................................................................... 4
Name of Instrument
This instrument is the Australian Medical Research and Innovation Priorities 2016 – 2018 Determination 2016.
Commencement
This instrument commences on the day after it is registered.
Cessation
This instrument will cease to be in force as if repealed at the end of two years after the instrument is registered.
Authority
This instrument is made under subsection 32E(1) of the Medical Research Future Fund Act 2015.
Schedules
Schedule 1 to this determination contains the Australian Medical Research and Innovation Priorities 2016 – 2018.
Schedule 1
AUSTRALIAN MEDICAL RESEARCH
AND INNOVATION PRIORITIES
2016-2018
Australian Medical Research and Innovation Priorities 2016-2018
Under the Medical Research Future Fund Act 2015, the Health Minister must take this document (Australian Medical Research and Innovation Priorities 2016-2018) into account when making decisions relating to financial assistance provided from the Medical Research Future Fund (MRFF). The Australian Medical Research Advisory Board has constructed this initial list of priorities to be read and considered in conjunction with the Australian Medical Research and Innovation Strategy 2016-2021.
| Strategic and international horizons | |
| Antimicrobial resistance | Investment in this global challenge, consistent with Australia’s First National Antimicrobial Resistance Strategy (2015–2019), with a focus on research to bring to market point-of-care solutions. |
| International collaborative research | Create a reserve for rapid funding of international collaborative work in priority areas of health and medical research, capable of leveraging multiple agency, discipline, national or industry investment. |
| Disruptive technology | Assess the impact of disruptive technologies such as artificial intelligence, wearables, genomic engineering and emerging markets on health service delivery and health training requirements. |
| Data and infrastructure | |
| Clinical quality registries | Provide start-up investment in disease or therapy-focussed clinical registries supported by a national framework to maximise interoperability and value of research to clinical practice. |
| National data management study | Study, in collaboration with key agencies, the requirements for infrastructure enhancement that expands the use of secure, digitised (My Health Record) and linked health and social data and inter-agency collaborative research. |
| MRFF infrastructure and evaluation | Establish: (1) a consumer-driven health and medical research agenda; (2) a method to guide future MRFF priorities; and (3) the means to measure and report on economic returns from investments. |
| Communicable disease control | Enhance and coordinate research on national surveillance of and response to current and emerging infectious diseases and antimicrobial resistance. |
| Health services and systems | |
| National Institute of Research | In partnership with the states and territories, determine the feasibility of establishing a national institute focused on health services, and public and preventive health research to facilitate evidence-based and cost-effective healthcare. |
| Building evidence in primary care | Work alongside the Medicare Benefits Schedule Review Taskforce to identify interventions with limited supporting evidence that are amenable to randomised control trial investigations, and engage the existing workforce to build capacity. |
| Behavioural economics application | Support development of research in applied behavioural economics that concentrates on public and preventive health, with an emphasis on early intervention in mental health, healthy eating and physical activity. |
| Drug effectiveness and repurposing | Invest in post-clinical effectiveness studies of drugs and other health interventions and support pre-clinical proposals that identify new uses for existing drugs. |
| Capacity and collaboration | |
| National infrastructure sharing scheme | Develop and evaluate a national scheme that enables researchers to locate and access existing high cost infrastructure to maximise hardware use and foster research collaboration. |
| Industry exchange fellowships | Connect industry and academia via PhD and postdoctoral fellowships to enable and encourage talent exchange, with the aim of stimulating entrepreneurial and translation capabilities. |
| Clinical researcher fellowships | Expand the scope and scale of the existing NHMRC Practitioner Fellowships Scheme to increase engagement of research-focussed clinicians in problem-solving and the translation of research into clinical practice. |
| Trials and translation | |
| Clinical trial network | Provide infrastructure support for existing and new national clinical trial networks to enhance innovation, collaboration, clinical research capacity and patient participation. |
| Public good demonstration trials | Invest in extension of clinical trials of proven therapies with limited opportunity for further commercial sponsorship to at-risk groups including adolescents and young adults, culturally diverse groups, and people with complex co‑morbidities. |
| Targeted translation topics | Work with the NHMRC-accredited Advanced Health Research and Translation Centres to deliver research agendas in primary care, acute and sub-acute settings relating to: · clinical pathways and care transition; · clinical variation; · co-morbidity; and · health inequities in Aboriginal and Torres Strait Islander Australians and other vulnerable populations. |
| Commercialisation | |
| Research incubator hubs | Create and evaluate virtual or actual health research incubator hubs that stimulate partnerships across a range of academic, clinician and industry stakeholders to generate early-stage research ideas for diagnostics, devices and molecular therapeutics. |
| Biomedical translation | Through the Biomedical Translation Fund, seek out matched private capital to invest via licensed fund managers in pre-clinical to early clinical translation of research of commercial value. |
0
0
0